Group 1 - The company Guangzheng Eye Hospital (SZ 002524) held its sixth fifth board meeting on August 19, 2025, to review the 2025 semi-annual report and summary [1] - For the first half of 2025, the company's revenue composition was as follows: 91.5% from the health industry, 5.46% from steel structure engineering, and 3.04% from the energy sector [1] - As of the report, Guangzheng Eye Hospital has a market capitalization of 2.5 billion yuan [1]

Group 1 - The latest stock price of Guangzheng Eye Hospital is 4.78 yuan, up 1.70% from the previous trading day, with a highest intraday price of 4.79 yuan and a lowest of 4.70 yuan, and a trading volume of 148,450 hands, amounting to 0.71 billion yuan [1] - The company’s main business includes ophthalmic medical services, steel structure, and energy business, focusing on investment and operation management of eye hospitals, creating a comprehensive diagnostic and treatment service system [1] - The steel structure business is concentrated in the green, low-carbon, energy-saving, and environmental protection sectors [1] Group 2 - In the first half of 2025, the company reported an operating income of 4.36 billion yuan and a net profit attributable to shareholders of 141.89 million yuan, representing a year-on-year growth of 11.38% [1] - The sixth session of the supervisory board's fifth meeting approved multiple proposals [1] Group 3 - On August 21, the main funds experienced a net outflow of 528,500 yuan, but over the past five days, there has been a net inflow of 10.51 million yuan [1]

（文章来源：证券日报） 证券日报网讯 8月21日晚间，光正眼科发布公告称，公司第六届监事会第五次会议审议通过了《关于工 商变更企业类型并修订的议案》等多项议案。 ...

Group 1 - The company, Guangzheng Eye Hospital (002524.SZ), reported a revenue of 436 million yuan for the first half of the year, representing a year-on-year decline of 9.49% [1] - The net profit attributable to shareholders of the listed company was 1.4189 million yuan, showing a year-on-year increase of 11.38% [1] - The company experienced a non-recurring net loss of 3.2798 million yuan [1]

天眼查显示，近日，厦门思明星光灼灼眼科诊所有限公司成立，法定代表人为林水龙，注册资本250万 人民币，由厦门星光卓越医疗管理有限公司全资持股。 经营范围含诊所服务；眼镜销售（不含隐形眼镜）；眼镜制造；第一类医疗器械销售；第二类医疗器械 销售；光学仪器销售；电子专用材料销售；功能玻璃和新型光学材料销售；健康咨询服务（不含诊疗服 务）；保健食品（预包装）销售。（除依法须经批准的项目外，凭营业执照依法自主开展经营活动）许 可项目：医疗服务；第三类医疗器械经营。（依法须经批准的项目，经相关部门批准后方可开展经营活 动，具体经营项目以相关部门批准文件或许可证件为准）。 企业名称厦门思明星光灼灼眼科诊所有限公司法定代表人林水龙注册资本250万人民币国标行业卫生和 社会工作>卫生>医院地址厦门市思明区吕岭路1583号宝龙一城一期1-6号楼第L2层S1-L2-002之二企业类 型有限责任公司（自然人投资或控股的法人独资）营业期限2025-8-20至无固定期限登记机关 来源：金融界 序号股东名称持股比例1厦门星光卓越医疗管理有限公司100% ...

Core Points - The company, Guangzheng Eye Hospital Group Co., Ltd., has announced a supplementary notice regarding the second extraordinary general meeting of shareholders for the year 2025, scheduled for September 4, 2025 [1][2] - The controlling shareholder, Guangzheng Investment Co., Ltd., will submit a temporary proposal to amend the company's articles of association at the upcoming meeting [1][2] - The meeting will allow shareholders to vote either in person or via an online voting platform provided by the Shenzhen Stock Exchange [2][5] Meeting Details - The extraordinary general meeting will take place on September 4, 2025, at 15:00, with online voting available from 9:15 to 11:30 on the same day [2][3] - Shareholders must register to attend the meeting, with specific procedures outlined for both individual and corporate shareholders [3][4] - Voting will be conducted through a single method, either in-person or online, and duplicate votes will be disregarded, with the first valid vote counted [3][6] Proposals for Discussion - The agenda includes a proposal for the repurchase and cancellation of part of the restricted stock incentive plan from 2023, which has already been approved by the company's supervisory board [3][8] - Another proposal involves changing the company's business type and amending the articles of association, which will also be presented for approval [8]

Core Viewpoint - The company reported a decline in operating revenue for the first half of 2025, while net profit showed an increase, indicating mixed financial performance [1] Financial Performance - Operating revenue for the first half of 2025 was 436 million yuan, representing a year-on-year decrease of 9.49% [1] - Net profit for the same period was 1.4189 million yuan, reflecting a year-on-year increase of 11.38% [1]

Group 1 - The stock price of Aier Eye Hospital closed at 13.24 yuan on August 20, 2025, reflecting a 1.22% increase from the previous trading day, with a trading volume of 1.389 billion yuan and a fluctuation of 2.52% [1] - Aier Eye Hospital is a leading ophthalmology medical chain in China, offering services in refractive surgery, cataract treatment, and vision care [1] - The Shanghai Aier Eye Hospital has introduced a plasma coating care technology that can repair scratched corneal reshaping lenses (OK lenses), effectively reducing the cost for parents to replace lenses. This technology cleans the lens surface using low-temperature argon plasma, achieving a sterilization rate of over 90%, and has already helped over a hundred children extend the lifespan of their lenses in outpatient settings [1] Group 2 - On August 20, Aier Eye Hospital saw a net inflow of 23.5613 million yuan in main funds, while there was a net outflow of 1.79 billion yuan over the past five days [2]

8月18日，何氏眼科主力资金净流出35.69万元，占流通市值的0.02%。近五个交易日，主力资金累计净 流出713.40万元，占流通市值的0.36%。 风险提示：股市有风险，投资需谨慎。 来源：金融界 截至2025年8月18日15时0分，何氏眼科最新股价为23.78元，较前一交易日上涨0.30元，涨幅1.28%。当 日开盘价为23.60元，最高触及23.96元，最低下探23.49元，成交量为24947手，成交额0.59亿元。 何氏眼科属于医疗服务板块，公司主营业务涵盖眼科医疗、视光服务及眼健康管理等领域。 ...

（文章来源：证券日报） 证券日报网讯爱尔眼科8月18日在互动平台回答投资者提问时表示，目前国内大多数中老年人对老花 （老视）治疗的认知程度不高，老花治疗在国内普及率极低，还处于启蒙阶段。与之对应的是，欧洲地 区对老花治疗的接受度较高，公司的欧洲子公司经验丰富，老花手术业务发展良好。为了适应人口老龄 化背景下的大量新需求，公司结合海外团队经验积极发展老年眼病诊断、老视治疗等业务，已在多地爱 尔医院开设老视门诊，并将成立老视学组，为广大中老年人群提供适宜的视觉解决方案。随着适龄段人 群支付能力的提高和对视觉品质的追求，老花诊疗未来有望持续增长。 ...